Additional file 1 of Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

MLA

Sugimoto, Yuna, et al. Additional File 1 of Aripiprazole in the Real-World Treatment for Irritability Associated with Autism Spectrum Disorder in Children and Adolescents in Japan: 52-Week Post-Marketing Surveillance. Jan. 2021. EBSCOhost, https://doi.org/10.6084/m9.figshare.14471361.v1.

APA

Sugimoto, Y., Yamamura, K., Takayama, T., Fukuta, Y., Aoki, K., Katsunaka Mikami, & Tomoda, A. (2021). Additional file 1 of Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance. https://doi.org/10.6084/m9.figshare.14471361.v1

Chicago

Sugimoto, Yuna, Kayo Yamamura, Tomoyo Takayama, Yasuhiko Fukuta, Kazuo Aoki, Katsunaka Mikami, and Akemi Tomoda. 2021. “Additional File 1 of Aripiprazole in the Real-World Treatment for Irritability Associated with Autism Spectrum Disorder in Children and Adolescents in Japan: 52-Week Post-Marketing Surveillance,” January. doi:10.6084/m9.figshare.14471361.v1.